Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ERAS-0015 in RAS-mutant (RASm) solid tumors. The expected timing is based on the latest available company guidance and may change.
AURORAS-1 trial. 5/13/25- IND cleared by FDA. 8/12/25- Initial monotherapy data in 2026. 11/12/25:- Ph1 mono data still expected 2026. 01/12/26:- AURORAS-1 dose escalation shows early responses; initial Ph1 monotherapy data now planned for H1 2026. 02/24/26:- AURORAS-1 dose escalation shows favorable safety and responses; initial Ph1 monotherapy data still expected in H1 2026. 03/12/26:- AURORAS-1 and JYP0015M101 Ph1 mono data expected H1 2026; AURORAS-1 expansion and combo cohorts start H2 2026. 04/27/26:- Preliminary Ph1 dose-escalation AURORAS-1 data showed favorable safety, linear PK, and partial responses. Data disclosure expected H1 2027. 05/11/26:- Keytruda combo added to AURORAS-1; early dose escalation showed partial responses at 8 mg daily. 05/11/26:- Monotherapy expansion and panitumumab combo dose escalation ongoing; data from both expected H1 2027. 07/13/26:- 57% uORR in KRAS G12X PDAC; more mono and panitumumab-combo data expected H1 2027. 08/11/26:- AURORAS-1 update showed 57% uORR. Mono and combo data remain expected H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.